Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567. A Single-centre, Placebo-controlled, Randomised, Double-blind Study in Healthy Subjects

NCT06030375 is registered in ClinicalTrials.gov with Novakand Pharma AB as lead sponsor.

NCT NCT06030375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06030375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567. A Single-centre, Placebo-controlled, Randomised, Double-blind Study in Healthy Subjects
Lead sponsor
Novakand Pharma AB
Phase
Phase 1
Overall status
Completed
Start date
February 17, 2020
Completion date
April 27, 2020
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy